Top contract research organization Kendle reported a strong quarter but told Wall Street future profits would be lower than expected. Quarterly revenues jumped 33 percent to $100 million. The company lined up $175 million in new business. But net income slipped five percent to $3.8 million. Costs for the merger with Charles River were one issue during the period. “We are particularly pleased with the strong increase in our operating margin,” noted Candace Kendle, chairman and CEO.  “We look forward to building on this momentum to deliver improved value for our shareholders.” The release is here. Contract research company Quintiles announced that its Latin American subsidiary has purchased Bio-Trials, a leading Central American contract research organization (CRO) with headquarters in Panama and offices in Costa Rica, Guatemala, Ecuador and Peru. Bio-Trials provides clinical monitoring, clinical site coordination, regulatory support, study management and supply distribution services. Jeff Thomis, president of global clinical…more...